Daniel Baram, MD
Critical Care Medicine · Columbia, MDNPI 1407881345
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,299 of the $4,957 with a category attached, or 86.7%. It is spread thinly across 14 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,165 and has fallen 89.8% since, to $119 in 2025. Among critical care medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $88.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Johnson & Johnson$725
- Sanofi$660
- Insmed, Inc.$537
- Boehringer Ingelheim$450
- GSK$421
- plus $1K from 8 others
What the payments were for
- Travel & lodging$65713%
- Food & beverage$4,29987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $1,052 |
| Johnson & Johnson | 7 | $725 |
| Sanofi | 6 | $660 |
| Insmed, Inc. | 5 | $537 |
| Boehringer Ingelheim | 4 | $450 |
| GSK | 6 | $421 |
| United Therapeutics Corporation | 3 | $298 |
| Bayer | 2 | $247 |
| Mylan Specialty L.p. | 2 | $220 |
| Grifols USA, LLC | 2 | $160 |
| Inspire Medical Systems, Inc. | 1 | $117 |
| Covidien LP | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Amgen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,957 in reported general payments places this provider in the 90th percentile of 231 critical care medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $72,282 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $40,053 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $19,592 |
| Spiriva HandihalerTiotropium Bromide | 20 | $15,501 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,828 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $9,383 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,559 |
| Advair DiskusFluticasone Propion/Salmeterol | 21 | $7,084 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $6,870 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 261 | $6,396 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,506 |
| Varenicline Tartrate | 15 | $3,092 |
| Ventolin HfaAlbuterol Sulfate | 28 | $2,035 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $1,712 |
| Fluticasone Propionate | 70 | $1,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $421 | $119,894162 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,052 | $28,97557 claims |
| Boehringer IngelheimSpiriva Respimat | $450 | $9,82814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 231 critical care medicine providers in Maryland.
Other critical care medicine in Columbia
- Christopher ChapmanMitchellville$248K
- David Feller KopmanBaltimore$236K
- Elizabeth HuntBaltimore$182K
- Robert BrowningBethesda$73K
- Edward BrittBaltimore$70K
- Lydia Gilbert-McclainBethesda$68K
- Nirav ShahBaltimore$55K
- Steven KellerBaltimore$31K
- Daniel BrodieBethesda$26K
- Nader HabashiBaltimore$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.